SBP has the scientific expertise and technology platforms necessary to develop new therapeutics that address unmet clinical needs of patients. Our journey starts at the beginning – establishing innovative disease targets – and continues until our drug therapies are ready for patient testing.
Our Drug Discovery Groups
Where do new medicines come from? In the past, large pharmaceutical companies were solely responsible for most drug discovery. Due to high costs and pressures to “fill the pipeline” faster, pharmaceutical companies frequently move away from drug discovery efforts that are deemed risky, especially for “orphan” diseases that are unprofitable for investors.
The Institute’s Cancer Center is one of only seven NCI-designated basic cancer research centers in the nation. We couple fundamental biological research with early translational studies to find new, innovative therapies that restore hope to cancer patients and their families.
Obesity constitutes a global pandemic, with the number of overweight and obese people worldwide rising from 857 million in 1980 to 2.1 billion in 2013. Global projections show diabetes cases increasing from 171 million in 2000 to 366 million in 2030.
Diseases associated with aging and development are already a leading cause of death and disability, and their prevalence is rising fast—to give one example, by 2050, the number of Alzheimer’s patients age 65 and older may nearly triple from 5 million to 13.8 million.
Genetic diseases in children are rare, and often incurable. Research insights into the genes and environmental factors that play a role in the development of childhood diseases is leading to better ways to more accurately diagnose, treat and cure children and young people with disease.
|A drug discovery pipeline is created in distinct stages. At SBP, we start at the beginning—establishing innovative disease targets—and continue until it’s time to test drugs in patients. At that point, we partner with organizations such as hospitals, clinical research organizations and pharmaceutical companies to conduct clinical trials in phases designed to answer specific research questions.|